A full-service healthcare organization delivering marketing, distribution, regulatory, research, clinical trial, and innovation capabilities under one platform.
End-to-end support across marketing, distribution, regulatory, research, and clinical operations.
Compliance capabilities covering FDA, EMA, EAEU, GCC and emerging-market standards.
Presence across the USA, GCC, Africa and Asia with strong partnerships and distribution channels.
Vilin Bio Med Inc is a US-based healthcare enterprise built on a fully integrated model. We combine marketing, distribution, regulatory services, research, clinical trial management and innovation to support the entire lifecycle of healthcare products.
Our core mission is to make high-quality, affordable, and innovative healthcare solutions accessible across global markets. We bridge science, technology and market expertise to support pharmaceutical, nutraceutical, biologics, food supplement, and hospital supply stakeholders worldwide.
Driving advancement in biologics, pharmaceuticals, nutraceuticals and HealthTech.
Meeting global regulatory standards across the USA, GCC, EU and emerging markets.
Serving partners across the USA, GCC, Africa and Asia.
Supporting manufacturers, healthcare institutions and innovators with scalable solutions.
To enable global access to high-quality healthcare products through reliable services, strong compliance and continuous innovation.
To build a unified healthcare platform that supports companies from research to commercialization with speed, efficiency and global reach.
Multi-segment integration — every service from product development to market launch operates within a single, accountable platform.
A connected suite of services that span product development, compliance, commercialization, clinical research and global sourcing — multi-segment by design, single-platform in execution.
Pan-regional distribution and market-entry support for pharmaceuticals, nutraceuticals, hospital supplies and supplements.
Compliance and safety expertise across global authorities and emerging markets.
Innovative R&D supporting advanced therapies and product development.
End-to-end clinical research for pharmaceuticals, biologics and nutraceuticals.
Reliable sourcing of ingredients and finished formulations from trusted partners.
Skill development for healthcare professionals, regulators and institutions.
Strategic partnerships for product development and market expansion.
AI-driven platforms for clinical research, pharmacovigilance and digital health.
Regulatory support, clinical research capabilities, sourcing, and market-entry solutions for manufacturers and distributors.
Development and commercialization of biologics in high-impact therapeutic areas.
End-to-end development, sourcing and distribution of high-quality supplements across global markets.
Procurement support, training and distribution of essential medical supplies for hospitals, clinics and networks.
Consistent supply of APIs, formulations, supplements and healthcare products across regional and international markets.
Support for digital health, data-driven platforms and AI models for healthcare innovation.
Collaboration with universities, CROs and research institutes engaged in clinical trials, regulatory science and applied innovation.
Vilin Bio Med Inc operates through a connected network of partners, distributors, research institutions and regulatory channels — built for reliable compliance, strong supply chains and scalable growth.
Office: Sheridan, Wyoming
Our primary operational base and front-end hub for regulatory, research and commercial activities.
UAE · Bahrain · Saudi Arabia · Qatar · Oman · Kuwait
A major strategic region supporting regulatory approvals, distribution and clinical collaborations.
Innovation & regulatory pathways
Emerging-market growth
India · China · Southeast Asia
Across all regions we collaborate with pharmaceutical manufacturers, research organizations, hospitals, academic institutions, nutraceutical brands and HealthTech innovators.
A flagship US R&D Centre in New Jersey to anchor Vilin Bio Med Inc's biologics, formulation and AI-driven healthcare programs at the heart of America's pharmaceutical corridor — translating Wyoming-headquartered governance into Princeton-corridor science.
Located in the densest concentration of pharmaceutical and life-sciences talent in the United States, the New Jersey R&D Centre will serve as the company's principal innovation engine for biologics, biosimilars, nutraceuticals, BE/BA studies and AI-enabled clinical research, with direct lines to FDA pathways, top-tier academic networks, and global manufacturing supply chains.
New Jersey hosts the densest cluster of pharmaceutical, biotech and medical-device organizations in the world — combining unmatched scientific talent, regulatory proximity, world-class logistics, and the demographic diversity required for representative clinical research.
Concentration of global pharmaceutical, biotech and CRO operations enabling co-development, talent mobility and partnership velocity.
Direct access to research talent and networks at Rutgers, Princeton, NJIT and the broader NY metro academic ecosystem.
Operational closeness to FDA hubs, advisory networks and the Mid-Atlantic regulatory community — built for IND/NDA/ANDA programs.
Port of NY/NJ, Newark Liberty International, and a top-tier cold-chain ecosystem for biologics, APIs and clinical samples.
One of the most diverse populations in the US — uniquely suitable for representative bioequivalence and Phase I–III recruitment.
Anchor for US investor relations, strategic partnerships and the company's planned cross-listing and capital-markets pathway.
Natural east-coast bridge to our GCC, EU and Asia operations — closing the loop between sourcing, R&D and commercialization.
Eligibility for NJEDA innovation programs, life-sciences incentives and shared infrastructure across the state's biotech parks.
Designed as a vertically integrated facility — discovery, formulation, analytical, clinical operations and AI compute under one roof.
Cell-line development, upstream/downstream process development, characterization and analytical comparability.
Oral solids, injectables, specialty dosage forms and nutraceutical formulations across stability and scale-up programs.
HPLC/UPLC, mass spectrometry, dissolution, microbiology and bio-assay capabilities under ISO 17025 alignment.
Bioequivalence and bioavailability studies aligned with FDA, EMA and WHO guidelines, executed via partner clinics.
Phase I–IV trial design, site management, monitoring and IND/NDA/ANDA submission support.
AI-enabled trial design, pharmacovigilance signal detection, predictive analytics and drug discovery workflows.
FDA, EMA and emerging-market submission readiness, life-cycle management and compliance training.
Nutraceutical and functional-food product development, claim substantiation and stability programs.
Joint programs with academic medical centres, hospitals and CROs across the NY/NJ region.
The R&D Centre will be funded through a blend of internal capital, strategic co-development partnerships, and qualified state-level life-sciences incentives — with each phase tied to clear scientific, regulatory and commercial milestones.
Figures are indicative planning estimates for the proposal stage and will be refined in the Detailed Project Report.
Faster time-to-IND for biologics and biosimilar programs, with shared infrastructure across nutraceuticals and functional foods.
In-house FDA-aligned capability strengthens NDA/ANDA throughput and supports global filings across GCC, EU and emerging markets.
A US-anchored hub for joint programs with global pharma, biotech and HealthTech partners.
Operational AI platforms for clinical trials, pharmacovigilance and discovery — productized into Vilin's HealthTech business.
A destination employer for US life-sciences talent, anchored by the New Jersey/NY metro academic ecosystem.
Reinforces the cross-listing thesis with a tangible, US-based scientific and operational footprint.
We welcome conversations with strategic partners, co-development sponsors, state agencies and institutional investors interested in shaping this initiative.
Establishing a GCC hub in Bahrain for oncology and chronic disease products.
Expanding the US portfolio with biologics, biosimilars and health supplements.
Launching AI-driven platforms for pharmacovigilance and clinical research.
Forming co-development alliances across the EU, India and the USA.
Preparing for global IPO and cross-listing opportunities.
Vilin Bio Med Inc offers exposure to the most resilient and fastest-growing segments of global healthcare — built on integrated capabilities, multiple revenue streams, and clear international exit pathways.
Get in touch ↗Pharma, Biologics, Nutraceuticals, AI HealthTech and Clinical Trials — within a single integrated platform.
Driven by R&D assets, contract trials and distributed product portfolios.
De-risks single-segment exposure and enhances long-term stability.
Including IPO and international cross-listing opportunities.
From product development to market launch, all services connect within a single platform.
R&D depth combined with strong regulatory discipline that meets global standards.
Presence across the USA, GCC, Africa and Asia enables faster commercialization.
In-house and collaborative clinical structures support faster time-to-market.
Vilin Bio Med Limited has entered into a marketing agreement with Activpower Inc. (Virginia, USA) to support the marketing and distribution of Activpower's products in the United States through our U.S. subsidiary, Vilin Bio Med Inc. (Wyoming, USA).
Vilin Bio Med Limited has entered into a Product Manufacturing and Supply Agreement with Westminster Pharmaceuticals Inc., USA, to support the manufacturing and long-term supply of select pharmaceutical products for the U.S. market.
We support the full lifecycle of healthcare products — distribution, regulatory, research, clinical trials, sourcing and innovation. Our integrated model helps companies enter new markets with confidence and scale globally.
